Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-12-26
2006-12-26
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S634000
Reexamination Certificate
active
07153887
ABSTRACT:
The invention describes the use of deoxyspergualin (DSG) or an analogue thereof for the preparation of a medicament for the treatment of and/or prophylaxis against hyperreactive inflammatory diseases and autoimmune diseases, wherein the treatment is performed in cycles.
REFERENCES:
patent: 5250442 (1993-10-01), Cabezas
patent: 5624938 (1997-04-01), Pernis
patent: 5679651 (1997-10-01), Richardson
patent: 6083503 (2000-07-01), Lenardo
patent: 197 11 803 (1998-09-01), None
patent: 197 28 436 (1999-01-01), None
patent: 0 673 646 (1995-09-01), None
patent: 0 678 297 (1995-10-01), None
patent: WO 99/03504 (1999-01-01), None
“Immunosuppressive Effect of Deoxyspergualin in Proliferative Glomerulonephritis”, Hotta et al., American Journal of Kidney Diseases, Nov. 1999, 34(5), 894-901.
“Unique Action of an Immunosuppressive Agent, Deoxyspergualin, One Hematopoiesis in Mice”, Memoto et al., Experimental Hematology, 1997, 25(13), 1339-1346.
“Deoxyspergualin: A New Immunosuppressive Drug for the Treatment of Autoimmune Disease”, Nikolic-Paterson et al., Nephron 1995, 70(4), 391-6.
“Effect of 15-Deoxyspergulain on Graft-V-Host Disease in Mice”, Nemoto et al., Transplant Proc., 1987, 19(5), 3985-6.
Positive Results of Phase I Study Put LymphoStat-B on Fact Track for Drug Development, 2001, Lupus Foundation of America, Inc.
“Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System”, Vandana Mathrani,2000 Third Web Report On Seredip.
“Autoimmune Diseases Poorly Understood, Difficult to Treat”, CNN.com, Jul. 4, 2000.
“Tips for Getting a Proper Diagnosis of Autoimmune Disease”, Infocus, Vo. 10, No. 2, Jun. 2002.
“Autoimmune Diseases: Overview”, The National Woment's Health Information Center, Oct. 2003, 2000.
Okada et al, “Immunosuppressant Deoxyspergualin Induces Apoptotic Cell Death in Dividing Cells”, Immunology 1998, pp. 370-376.
Schorlemmer et al, “Preclinical Studies with 15-Deoxyspergualin in Various Animal Models for Autoimmune Diseases”, Animals of the New York Academy of Sciences, vol. 685, 1993, pp. 155-174, also referred to as XP 000974478.
Schorlemmer et al, “Curative Effects of 15-Deoxyspergualin on Murine Systemic Lupus Erythematosus-Like Disease in MRL/1 Autoimmune Mice”, International Journal of Immunotherapy, vol. 7, No. 4, 1991, pp. 169-180, also referred to as XP 000974488.
Lebreton et al, “Structure-Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Stuctural Modifications of the Hydroxyglycine Moiety”, Journal of Medicinal Chemistry, American Chemical Society, vol. 42, Jan. 28, 1996, pp. 277-290, also referred to as XP 000971394.
Schorlemmer et al, “Immunosuppressive Activity of 15- Deoxyspergualin (15-DOS) on Various Models of Rheumatoid Arthritis”, Drugs under Experimental and clinical Research, vol. 17, No. 10/11, 1991, pp. 471-483, also referred to as XP 00097446.
Schorlemmer et al, “Immunosuppressive Therapy of Organ-Specific Nephritic Autoimmune Diseases with 15- Deoxyspergualin”, Agents and Actions, vol. 39, 1993, pp. C121-C124, also referred to as XP 000974491.
Katayama, “Experimental Lung Transplantation in Rats: Antirejection Effects of FK506 and 15-Deoxyspergualin”, MIE Medical Journal, vol. 40, No. 2, Aug. 1990, pp. 215-228, also referred to as XP 000974487.
Goral et al, “15 Deoxyspergualin Prolongs Survival During Acute Graft Versus Host Disease”, Journal of Allergy and Clinical Immunology, vol. 99, No. 1, 1997, also referred to as XP 000957371.
Choi et al, “Immunomodulator Therapy in Inflammatory Bowel Disease”, Digestive Diseases and Sciences, 1994, vol. 39, No. 9, also referred to as XP 000974490.
Birck et al, “15- Deoxyspergualin Induces Remission in Wegener's Granulomatosis: Report of Three Cases”, Journal of the American Society of Nephrology, vol. 10, Sep. 1999, also referred to as XP 000974913.
Bumgardner et al, “New Immunosuppressive Agents”, Gastroenterology Clinics of North America, vol. 22, No. 2, 1993, also referred to as XP 000974492.
Schorlemmer et al, “15 Deoxyspergualin—15-DOS) Has a Curative Effect on the Development of SLE-Like Autoimmune Disease in MRL/1Mice”, Agents and Actions, vol. 34, No. 1/02, 1991, pp. 151-155, also referred to as XP 000974941.
Kalden et al, “Immunological Treatment of Autoimmune Diseases”, Advances in Immunology, vol. 68, 1998, pp. 333-418, also referred to as XP 000974494.
Transplantation, vol. 51, p. 712-715, 1991.
Drugs Exp. Clin. Res., vol. 17, p. 471-483, 1991.
Drugs Exp. Clin. Res., vol. 17, p. 461-469, 1991.
Clin. Exp. Immunol., vol. 91, p. 232-236, 1993.
Scand. J. Immunol., vol. 36, p. 415-420, 1992.
J. Am. Soc. Nephrol., vol. 3, p. 1765-1774, 1993.
Clin. Exp. Immunol., vol. 95, p. 502-808, 1994.
Agents Actions, vol. 39, p. C121-C124, 1993.
Scand. J. Immunol., vol. 39, p. 333-336, 1994.
J. Neuro. Sci., vol. 112, p. 209-215, 1992.
Auotimmunity, vol. 8, p. 43-51, 1990.
Birck Rainer
Drexler Johannes
Hotta Osamu
Nowack Rainer
van der Woude Johannes Fokku
Euro Nippon Kayaku GmbH
Frommer & Lawrence & Haug LLP
Kwon Brian
Nippon Kayaku Kabushiki Kaisha
LandOfFree
Use of 15-deoxyspergualin for the treatment of ANCA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 15-deoxyspergualin for the treatment of ANCA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 15-deoxyspergualin for the treatment of ANCA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701430